PGNY vs UNH

For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.

8% revenue growth year-over-year, versus 10. 4% for Progyny, Inc. (PGNY). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 8x trailing P/E (20. 1x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.

8x versus Progyny, Inc. at 28. 8x. On forward P/E, Progyny, Inc. is actually cheaper at 16. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, UnitedHealth Group Incorporated (UNH) delivered a total return of -2.

5%, compared to -64. 1% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: UNH returned +220. 3% versus PGNY's +17. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), UnitedHealth Group Incorporated (UNH) is the lower-risk stock at 0.

59β versus Progyny, Inc. 's 0. 71β — meaning PGNY is approximately 21% more volatile than UNH relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 77% for UnitedHealth Group Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.

8% versus 10. 4% for Progyny, Inc. (PGNY). On earnings-per-share growth, the picture is similar: Progyny, Inc. grew EPS 14. 0% year-over-year, compared to -14. 7% for UnitedHealth Group Incorporated. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Progyny, Inc.

(PGNY) is the more profitable company, earning 4. 5% net margin versus 2. 7% for UnitedHealth Group Incorporated — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 4. 2% for UNH. At the gross margin level — before operating expenses — PGNY leads at 23. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Progyny, Inc.

(PGNY) trades at 16. 0x forward P/E versus 20. 1x for UnitedHealth Group Incorporated — 4. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 64. 7% to $30. 80.

In this comparison, UNH (2.

4% yield) pays a dividend. PGNY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, UnitedHealth Group Incorporated (UNH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

59), 2. 4% yield, +220. 3% 10Y return). Both have compounded well over 10 years (UNH: +220. 3%, PGNY: +17. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

UNH pays a dividend while PGNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.